These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8676459)

  • 1. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1.
    Shibata R; Siemon C; Cho MW; Arthur LO; Nigida SM; Matthews T; Sawyer LA; Schultz A; Murthy KK; Israel Z; Javadian A; Frost P; Kennedy RC; Lane HC; Martin MA
    J Virol; 1996 Jul; 70(7):4361-9. PubMed ID: 8676459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus.
    Girard M; van der Ryst E; Barré-Sinoussi F; Nara P; Tartaglia J; Paoletti E; Blondeau C; Jennings M; Verrier F; Meignier B; Fultz PN
    Virology; 1997 May; 232(1):98-104. PubMed ID: 9185593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
    J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.
    Girard M; Meignier B; Barré-Sinoussi F; Kieny MP; Matthews T; Muchmore E; Nara PL; Wei Q; Rimsky L; Weinhold K
    J Virol; 1995 Oct; 69(10):6239-48. PubMed ID: 7666524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies.
    Nishimura Y; Igarashi T; Haigwood N; Sadjadpour R; Plishka RJ; Buckler-White A; Shibata R; Martin MA
    J Virol; 2002 Mar; 76(5):2123-30. PubMed ID: 11836389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.
    Nara PL; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Gallo RC; Fischinger PJ; Goudsmit J
    J Virol; 1990 Aug; 64(8):3779-91. PubMed ID: 2370681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.
    Berman PW; Murthy KK; Wrin T; Vennari JC; Cobb EK; Eastman DJ; Champe M; Nakamura GR; Davison D; Powell MF; Bussiere J; Francis DP; Matthews T; Gregory TJ; Obijeski JF
    J Infect Dis; 1996 Jan; 173(1):52-9. PubMed ID: 8537682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain.
    Girard M; Yue L; Barré-Sinoussi F; van der Ryst E; Meignier B; Muchmore E; Fultz PN
    J Virol; 1996 Nov; 70(11):8229-33. PubMed ID: 8892959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees.
    Gibbs CJ; Peters R; Gravell M; Johnson BK; Jensen FC; Carlo DJ; Salk J
    Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3348-52. PubMed ID: 2014254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.
    Boyer JD; Ugen KE; Wang B; Agadjanyan M; Gilbert L; Bagarazzi ML; Chattergoon M; Frost P; Javadian A; Williams WV; Refaeli Y; Ciccarelli RB; McCallus D; Coney L; Weiner DB
    Nat Med; 1997 May; 3(5):526-32. PubMed ID: 9142121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1.
    Dunn CS; Hurtrel B; Beyer C; Gloeckler L; Ledger TN; Moog C; Kieny MP; Mehtali M; Schmitt D; Gut JP; Kirn A; Aubertin AM
    AIDS Res Hum Retroviruses; 1997 Jul; 13(11):913-22. PubMed ID: 9223407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees.
    Bogers WM; Koornstra WH; Dubbes RH; ten Haaft PJ; Verstrepen BE; Jhagjhoorsingh SS; Haaksma AG; Niphuis H; Laman JD; Norley S; Schuitemaker H; Goudsmit J; Hunsmann G; Heeney JL; Wigzell H
    J Gen Virol; 1998 Dec; 79 ( Pt 12)():2895-903. PubMed ID: 9880002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.
    Arthur LO; Bess JW; Waters DJ; Pyle SW; Kelliher JC; Nara PL; Krohn K; Robey WG; Langlois AJ; Gallo RC
    J Virol; 1989 Dec; 63(12):5046-53. PubMed ID: 2555541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2.
    el-Amad Z; Murthy KK; Higgins K; Cobb EK; Haigwood NL; Levy JA; Steimer KS
    AIDS; 1995 Dec; 9(12):1313-22. PubMed ID: 8605050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of SHIV for testing HIV-1 vaccine candidates in macaques.
    Lu Y; Salvato MS; Pauza CD; Li J; Sodroski J; Manson K; Wyand M; Letvin N; Jenkins S; Touzjian N; Chutkowski C; Kushner N; LeFaile M; Payne LG; Roberts B
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):99-106. PubMed ID: 8680896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.
    Robert-Guroff M; Kaur H; Patterson LJ; Leno M; Conley AJ; McKenna PM; Markham PD; Richardson E; Aldrich K; Arora K; Murty L; Carter L; Zolla-Pazner S; Sinangil F
    J Virol; 1998 Dec; 72(12):10275-80. PubMed ID: 9811775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus load in chimpanzees infected with human immunodeficiency virus type 1: effect of pre-exposure vaccination.
    ten Haaft P; Cornelissen M; Goudsmit J; Koornstra W; Dubbes R; Niphuis H; Peeters M; Thiriart C; Bruck C; Heeney JL
    J Gen Virol; 1995 Apr; 76 ( Pt 4)():1015-20. PubMed ID: 9049351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.